In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...
Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.Over 80% of lung ...
Canadian biotech Oncolytics Biotech (Nasdaq: ONCY) has reported encouraging clinical and translational data for its oncolytic ...
Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...
When treated with KRAS inhibitors alone, cancer cells can escape destruction by using the salvage pathway to gather ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Ka, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity ...
BridgeBio (BBIO) announced late-breaking preclinical data on BBO-10203, a covalent small molecule RAS:PI3Ka breaker that selectively and ...
Garsorasib shrank tumours in nearly half of patients with KRAS G12C pancreatic cancer and showed manageable side effects.
The microbial toxin colibactin has just the right shape to snuggle up to DNA — but its embrace is unfortunately more cancerous than cozy. Colibactin is produced by bacteria in the gut and causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback